MARKET

PYXS

PYXS

Pyxis Oncology, Inc.
NASDAQ
1.370
+0.020
+1.48%
After Hours: 1.420 +0.05 +3.65% 19:17 03/06 EST
OPEN
1.360
PREV CLOSE
1.350
HIGH
1.390
LOW
1.330
VOLUME
273.55K
TURNOVER
--
52 WEEK HIGH
5.55
52 WEEK LOW
0.8332
MARKET CAP
85.30M
P/E (TTM)
-0.8696
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PYXS last week (0223-0227)?
Weekly Report · 6d ago
Weekly Report: what happened at PYXS last week (0216-0220)?
Weekly Report · 02/23 09:23
Weekly Report: what happened at PYXS last week (0209-0213)?
Weekly Report · 02/16 09:23
Weekly Report: what happened at PYXS last week (0202-0206)?
Weekly Report · 02/09 09:23
Pyxis Oncology Announces Interim CEO Amid Leadership Transition
TipRanks · 02/06 21:35
Pyxis Oncology Appoints Thomas Civik as Interim CEO
Reuters · 02/06 21:08
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS)
TipRanks · 02/04 14:50
Pyxis Oncology appoints board member Thomas Civik as Interim CEO
TipRanks · 02/03 12:00
More
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.

Webull offers Pyxis Oncology Inc stock information, including NASDAQ: PYXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PYXS stock methods without spending real money on the virtual paper trading platform.